Terms: = Germ cell tumor AND BRAF, MGC126806, 673, ENSG00000157764, MGC138284, RAFB1, P15056, B-raf 1, BRAF1, B-raf1 AND Diagnosis
736 results:
1. braf-Mutated Melanoma Journey in Latin America: Expert Recommendations From diagnosis to Treatment.
Bravo-Garzón MA; Bornstein-Quevedo L; Camargo VP; Sanku G; Jansen AM; Macedo MP; Rico-Restrepo M; Chacón M
Cancer Control; 2024; 31():10732748241251572. PubMed ID: 38751033
[TBL] [Abstract] [Full Text] [Related]
2. Genetics-guided therapy in neuroendocrine carcinoma: response to braf- and MEK-inhibitors.
Falkman L; Sundin A; Skogseid B; Botling J; Bernardo Y; Wallin G; Zhang L; Welin S; Lase I; Mollazadegan K; Crona J
Ups J Med Sci; 2024; 129():. PubMed ID: 38716076
[TBL] [Abstract] [Full Text] [Related]
3. Clinical, Morphological and Molecular Features of Spitz tumors.
Donati M; Mansour B; Hagstrom M; Gerami P; Kazakov DV
Cesk Patol; 2024; 60(1):35-48. PubMed ID: 38697826
[TBL] [Abstract] [Full Text] [Related]
4. Multi-omics technologies and molecular biomarkers in brain tumor-related epilepsy.
Du Y; Li R; Fu D; Zhang B; Cui A; Shao Y; Lai Z; Chen R; Chen B; Wang Z; Zhang W; Chu L
CNS Neurosci Ther; 2024 Apr; 30(4):e14717. PubMed ID: 38641945
[TBL] [Abstract] [Full Text] [Related]
5. braf Mutated and Morphologically Spitzoid tumors, a Subgroup of Melanocytic Neoplasms Difficult to Distinguish From True Spitz Neoplasms.
Gerami P; Chen A; Sharma N; Patel P; Hagstrom M; Kancherla P; Geraminejad T; Olivares S; Biswas A; Bosenberg M; Busam KJ; de La Fouchardière A; Duncan LM; Elder DE; Ko J; Landman G; Lazar AJ; Lowe L; Massi D; Mihic-Probst D; Parker DC; Scolyer RA; Shea CR; Zembowicz A; Yun SJ; Blokx WAM; Barnhill RL
Am J Surg Pathol; 2024 May; 48(5):538-545. PubMed ID: 38525831
[TBL] [Abstract] [Full Text] [Related]
6. Molecular Frontiers in Melanoma: Pathogenesis, diagnosis, and Therapeutic Advances.
Kim HJ; Kim YH
Int J Mol Sci; 2024 Mar; 25(5):. PubMed ID: 38474231
[TBL] [Abstract] [Full Text] [Related]
7. Noninvasive Molecular Subtyping of Pediatric Low-Grade Glioma with Self-Supervised Transfer Learning.
Tak D; Ye Z; Zapaischykova A; Zha Y; Boyd A; Vajapeyam S; Chopra R; Hayat H; Prabhu SP; Liu KX; Elhalawani H; Nabavizadeh A; Familiar A; Resnick AC; Mueller S; Aerts HJWL; Bandopadhayay P; Ligon KL; Haas-Kogan DA; Poussaint TY; Kann BH
Radiol Artif Intell; 2024 May; 6(3):e230333. PubMed ID: 38446044
[TBL] [Abstract] [Full Text] [Related]
8. Adult epithelioid glioblastoma exhibits an extremely poor prognosis and high frequency of SWI/SNF complex mutation: Insights from a retrospective study.
Xi S; Jiang S; Li H; Huang Q; Lu J; Zhang X; Li Z; Zeng J
Int J Cancer; 2024 Jul; 155(1):172-183. PubMed ID: 38411299
[TBL] [Abstract] [Full Text] [Related]
9. Restrospective reappraisal of the prognostic classification of spitzoid melanocytic neoplasms after braf and NRAS mutation characterisation: a single institution experience.
Moysset I; Castrejon N; Garcia-Herrera A; Castillo P; Marginet M; Teixido C; Podlipnik S; Albero-Gonzalez R; Montironi C; Navarro J; Rovira C; Puig S; Carrera C; Alos L
Histopathology; 2024 Jun; 84(7):1154-1166. PubMed ID: 38409889
[TBL] [Abstract] [Full Text] [Related]
10. Integrated Proteogenomics Uncover Mechanisms of Glioblastoma Evolution, Pointing to Novel Therapeutic Targets.
Li J; Shih LK; Brat DJ
Cancer Res; 2024 May; 84(9):1379-1381. PubMed ID: 38330148
[TBL] [Abstract] [Full Text] [Related]
11. Thyroid Cancer: A Review.
Boucai L; Zafereo M; Cabanillas ME
JAMA; 2024 Feb; 331(5):425-435. PubMed ID: 38319329
[TBL] [Abstract] [Full Text] [Related]
12. Primary Mucosal Melanoma: Clinical Experience from a Single Italian Center.
Falcone R; Verkhovskaia S; Di Pietro FR; Poti G; Samela T; Carbone ML; Morelli MF; Zappalà AR; di Rocco ZC; Morese R; Piesco G; Marchetti P; Failla CM; De Galitiis F
Curr Oncol; 2024 Jan; 31(1):588-597. PubMed ID: 38275835
[TBL] [Abstract] [Full Text] [Related]
13. Integrated proteogenomic characterization of glioblastoma evolution.
Kim KH; Migliozzi S; Koo H; Hong JH; Park SM; Kim S; Kwon HJ; Ha S; Garofano L; Oh YT; D'Angelo F; Kim CI; Kim S; Lee JY; Kim J; Hong J; Jang EH; Mathon B; Di Stefano AL; Bielle F; Laurenge A; Nesvizhskii AI; Hur EM; Yin J; Shi B; Kim Y; Moon KS; Kwon JT; Lee SH; Lee SH; Gwak HS; Lasorella A; Yoo H; Sanson M; Sa JK; Park CK; Nam DH; Iavarone A; Park JB
Cancer Cell; 2024 Mar; 42(3):358-377.e8. PubMed ID: 38215747
[TBL] [Abstract] [Full Text] [Related]
14. Cutaneous melanocytic tumor with CRTC1::TRIM11 fusion: a case report.
Duan R; He X; Ma X; Huang F; Hu X
Diagn Pathol; 2024 Jan; 19(1):8. PubMed ID: 38184586
[TBL] [Abstract] [Full Text] [Related]
15. Metastatic Undifferentiated Melanoma Mimicking a Primary Bone tumor: A Potential Diagnostic Pitfall.
Wills A; Dibbern M; Frierson HF; Raghavan SS
Am J Dermatopathol; 2024 Mar; 46(3):170-172. PubMed ID: 38170737
[TBL] [Abstract] [Full Text] [Related]
16. Analysis of Histomorphologic/Molecular Association and Immune Checkpoint Regulators in Epithelioid Glioblastoma and Pleomorphic Xanthoastrocytoma: Are These tumors Potential Candidates for Immune Checkpoint Blockade?
Mahajan S; Singh J; Dandapath I; Jha P; Chaturvedi S; Ahuja A; Bhardwaj M; Saran R; Garg A; Sharma MC; Manjunath N; Suri A; Sarkar C; Suri V
Appl Immunohistochem Mol Morphol; 2024 Feb; 32(2):84-95. PubMed ID: 38158760
[TBL] [Abstract] [Full Text] [Related]
17. EphB3 protein is a potential ancillary diagnostic biomarker for thyroid cancers.
Gao X; Zhang R; He Y; Wang X; Bao W; Feng X; Chai J; Wang J
Ann Diagn Pathol; 2024 Apr; 69():152262. PubMed ID: 38150866
[TBL] [Abstract] [Full Text] [Related]
18. Real-world management practices and characteristics of patients with advanced melanoma initiated on immuno-oncology or targeted therapy in the first-line setting during the period 2015-2018 in Greece. The 'SUMMER' study: a retrospective multicenter chart review project.
Bafaloukos D; Kouzis P; Gouveris P; Boukovinas I; Kalbakis K; Baka S; Kyriakakis G; Moschou D; Molfeta A; Demiri S; Mavroudis D; Spanoudi F; Dimitriadis I; Gogas H
Melanoma Res; 2024 Apr; 34(2):152-165. PubMed ID: 38092014
[TBL] [Abstract] [Full Text] [Related]
19. Systemic therapy timing and use in patients with advanced melanoma at the end of life: A retrospective cohort study.
van Lith PEA; Schreuder K; Jalving M; Reyners AKL; Been LB; Rácz E; Fransen HP; Louwman MWJ
J Dermatol; 2024 Apr; 51(4):584-591. PubMed ID: 38078557
[TBL] [Abstract] [Full Text] [Related]
20. A new subtype of diffuse midline glioma, H3 K27 and braf/FGFR1 co-altered: a clinico-radiological and histomolecular characterisation.
Auffret L; Ajlil Y; Tauziède-Espariat A; Kergrohen T; Puiseux C; Riffaud L; Blouin P; Bertozzi AI; Leblond P; Blomgren K; Froelich S; Picca A; Touat M; Sanson M; Beccaria K; Blauwblomme T; Dangouloff-Ros V; Boddaert N; Varlet P; Debily MA; Grill J; Castel D
Acta Neuropathol; 2023 Dec; 147(1):2. PubMed ID: 38066305
[TBL] [Abstract] [Full Text] [Related]
[Next]
